This product is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before using herbs, especially if you are pregnant, nursing, taking medications, or have a medical condition.
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Ashitaba (Angelica keiskei) is a perennial herb native to Japan used as a medicinal plant and health food with potential antithrombotic, anti-obesity, and antioxidant properties [PMID:29880082, PMID:38357325].
Background
Angelica keiskei Koidzumi, known as Ashitaba, is a large perennial herb from the Apiaceae family native to the Pacific coast of Japan [PMID:29880082, PMID:37242522, PMID:33628918]. It is utilized as a dietary supplement, health food, and traditional medicine in Asian countries, including Japan, Korea, and China [PMID:29880082, PMID:31658768].
Traditional uses
Traditionally used to treat dysuria, dyschezia, and dysgalactia, to restore vitality, and as a blood-sugar reducer [PMID:28439780, PMID:35637670].
Active compounds
The plant contains various bioactive constituents, most notably the prenylated chalcones 4-hydroxyderricin and xanthoangelol [PMID:25576957, PMID:27399234]. Other identified compounds include coumarins, flavanones, phenolics, acetylenes, sesquiterpenes (such as germacrene B and D), diterpenes, triterpenes, and quercetin 3-O-glucoside [PMID:29880082, PMID:3261 la, PMID:40142168, PMID:28439780].
Mechanism of action
Mechanisms include inhibition of PAI-1 production to maintain anticoagulant status [PMID:22038782], activation of p38 mitogen-activated protein kinase (MAPK) to stimulate myogenesis [PMID:31658768], and phosphorylation of AMP-activated protein kinase (AMPK) to inhibit lipogenesis [PMID:25406632]. It also targets BRAFV600E and PI3K to induce apoptosis in melanoma cells [PMID:29980517] and inhibits PTP1B [PMID:25891102].
Clinical evidence
Evidence BOverweight/Obesity
Encapsulated Ashitaba chalcone (16 mg) significantly reduced visceral fat area and waist circumference in overweight men and women over 12 weeks [PMID:38557440].
Evidence DThrombosis/Coagulation
Ashitaba exudate and xanthoangelol suppress PAI-1 levels and inhibit platelet aggregation in animal models [PMID:29441970, PMID:29708806, PMID:37862040].
Evidence DMuscle Atrophy
Ethanol extract of Ashitaba (250-500 mg/kg) alleviated dexamethasone-induced muscle atrophic damages in rats [PMID:31658768].
Evidence DMetabolic Syndrome/NAFLD
Ashitaba extract reduced body weight gain, fat deposition, and liver steatosis in high-fat diet-fed mice and NAFLD mouse models [PMID:25406632, PMID:37920601].
Safety & adverse effects
A 90-day rat study of yellow sap powder (8.45% chalcones) showed dose-related male rat-specific alpha 2-urinary globulin nephropathy and jejunal lymphangiectasia at 1000 mg/kg/day [PMID:25576957]. Genotoxicity assays (bacterial reverse mutation, chromosome aberration, and in vivo micronucleus) were negative [PMID:25576957, PMID:38469361].
Pregnancy & lactation
Target populations for some proposed uses exclude pregnant and lactating women [PMID:38469361].
Evidence summary
Evidence is primarily based on in vitro studies and animal models (Level D), with one small randomized controlled trial (Level B) supporting anti-obesity effects in humans.
PubMed sources
1.PMID: 29880082 (2018) — Possible antithrombotic effects of Angelica keiskei (Ashitaba). · Die Pharmazie
3.PMID: 25576957 (2015) — Toxicological assessment of Ashitaba Chalcone. · Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
4.PMID: 31658768 (2019) — A Chalcone from Ashitaba (Angelica keiskei) Stimulates Myoblast Differentiation and Inhibits Dexamethasone-Induced Muscle Atrophy. · Nutrients
No direct government monograph is available for this herb. The content below is AI-generated and has not been verified against an authoritative government source. Use the search links to check official sources before relying on this information.
6.PMID: 35637670 (2022) — Inhibitory activity of xanthoangelol isolated from Ashitaba (Angelica keiskei Koidzumi) towards α-glucosidase and dipeptidyl peptidase-IV: in silico and in vitro studies. · Heliyon
7.PMID: 29441970 (2016) — Anti-platelet effects of chalcones from Angelica keiskei Koidzumi (Ashitaba) in vivo. · Die Pharmazie
8.PMID: 25019280 (2014) — Bioassay-guided isolation and identification of anti-platelet-active compounds from the root of Ashitaba (Angelica keiskei Koidz.). · Natural product research
9.PMID: 30686791 (2019) — Angelica keiskei (Ashitaba) powder and its functional compound xanthoangelol prevent heat stress-induced impairment in sperm density and quality in mouse testes. · The Journal of reproduction and development
10.PMID: 29708806 (2019) — Ashitaba (Angelica Keiskei) Exudate Prevents Increases in Plasminogen Activator Inhibitor-1 Induced by Obesity in Tsumura Suzuki Obese Diabetic Mice. · Journal of dietary supplements
11.PMID: 37862040 (2023) — Supplementation with Ashitaba (Angelica keiskei) Yellow Stem Exudate Prevents Aging-Induced Thrombotic Tendencies and Systemic Inflammation Without Affecting Body Weight Gain in Mice. · Journal of medicinal food
12.PMID: 25891102 (2015) — PTP1B inhibitors from stems of Angelica keiskei (Ashitaba). · Bioorganic & medicinal chemistry letters
13.PMID: 29980517 (2018) — The Ashitaba (Angelica keiskei) Chalcones 4-hydroxyderricin and Xanthoangelol Suppress Melanomagenesis By Targeting BRAF and PI3K. · Cancer prevention research (Philadelphia, Pa.)
14.PMID: 32612020 (2020) — cDNA Cloning and Functional Analyses of Ashitaba (Angelica keiskei) Sesquiterpene Synthase Genes. · Journal of oleo science
15.PMID: 28439780 (2017) — Angelica keiskei, an emerging medicinal herb with various bioactive constituents and biological activities. · Archives of pharmacal research
16.PMID: 38557440 (2024) — Randomised, double-blind, parallel group comparison of Ashitaba (Angelica Keiskei) chalcone effects on visceral fat areas and waist circumference of overweight persons. · International journal of food sciences and nutrition
17.PMID: 37920601 (2023) — Exploring the underlying mechanisms of Ashitaba in the management of non-alcoholic fatty liver disease by integrating the analysis of transcriptomics and metabolomics. · Frontiers in medicine
18.PMID: 38357325 (2024) — The pharmacology activities of Angelica keiskei Koidzumi and its efficacy and safety in humans. · Heliyon
19.PMID: 38469361 (2024) — Safety of ashitaba sap as a Novel food pursuant to Regulation (EU) 2015/2283. · EFSA journal. European Food Safety Authority
21.PMID: 22452965 (2012) — Absorption and metabolism of 4-hydroxyderricin and xanthoangelol after oral administration of Angelica keiskei (Ashitaba) extract in mice. · Archives of biochemistry and biophysics
22.PMID: 10524357 (1999) — Effects of angiotensin I-converting enzyme inhibitor from Ashitaba (Angelica keiskei) on blood pressure of spontaneously hypertensive rats. · Journal of nutritional science and vitaminology
23.PMID: 40117946 (2025) — 4-Hydroxyderricin attenuates ischemic brain injury and neuroinflammation by upregulating haptoglobin expression in microglia. · Phytomedicine : international journal of phytotherapy and phytopharmacology
24.PMID: 29441323 (2018) — The ethanolic extract of ashitaba stem (Angelica keskei [Miq.] Koidz) as future antituberculosis. · Journal of advanced pharmaceutical technology & research
26.PMID: 38390941 (2024) — Angelica keiskei water extract Mitigates Age-Associated Physiological Decline in Mice. · Redox report : communications in free radical research
27.PMID: 37242522 (2023) — Angelica keiskei Impacts the Lifespan and Healthspan of Drosophila melanogaster in a Sex and Strain-Dependent Manner. · Pharmaceuticals (Basel, Switzerland)
28.PMID: 27399234 (2016) — A Review of the Medicinal Uses and Pharmacology of Ashitaba. · Planta medica
29.PMID: 38998937 (2024) — Pharmacophore Modeling and Binding Affinity of Secondary Metabolites from Angelica keiskei to HMG Co-A Reductase. · Molecules (Basel, Switzerland)
30.PMID: 33628918 (2021) — Complete chloroplast genome of Angelica keiskei (Umbelliferae). · Mitochondrial DNA. Part B, Resources